Coverart for item
The Resource Pediatric psychopharmacology for primary care, Mark A. Riddle ; contributing editors, Rebecca A. Baum [and seven others]

Pediatric psychopharmacology for primary care, Mark A. Riddle ; contributing editors, Rebecca A. Baum [and seven others]

Label
Pediatric psychopharmacology for primary care
Title
Pediatric psychopharmacology for primary care
Statement of responsibility
Mark A. Riddle ; contributing editors, Rebecca A. Baum [and seven others]
Creator
Contributor
Author
Editor
Subject
Language
eng
Summary
"Completely updated and revised, the second edition provides primary care physicians with practice-tested, condition-specific treatment recommendations for various childhood mental disorders"--Publisher's description
Cataloging source
YDX
http://library.link/vocab/creatorName
Riddle, Mark A
Dewey number
615.78083
Index
index present
LC call number
RJ504.7
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
NLM call number
WS 350.2
http://library.link/vocab/relatedWorkOrContributorName
Baum, Rebecca A.
http://library.link/vocab/subjectName
  • Pediatric psychopharmacology
  • Pediatric pharmacology
  • Mental Disorders
  • Child
  • Adolescent
  • Psychotropic Drugs
  • Pediatric pharmacology
  • Pediatric psychopharmacology
Label
Pediatric psychopharmacology for primary care, Mark A. Riddle ; contributing editors, Rebecca A. Baum [and seven others]
Instantiates
Publication
Copyright
Note
Revised edition of: Pediatric psychopharmacology for primary care / Mark A. Riddle ; contributing editors, Jane Meschan Foy [and seven others]. [2016]
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
Introduction -- What is this book? -- Selected updates in second edition -- Target audience -- Why now? -- Basic principles -- What about the future? -- Part I. Conceptual framework. Conceptual framework for prescribing psychotropic medications -- Rationale for the conceptual framework -- Group 1 medications for attention-deficit/hyperactivity disorder, anxiety, and depression -- Group 2 medications -- Group 3 medications -- Part II. Practical guidance. The psychosocial assessment in primary care -- Start with inquiry about normative developmental trajectory -- Triage for psychiatric and social emergencies -- Emphasize function -- Assess sleep pattern -- Identify environmental stressors -- Screen for substance use -- Differentiate new problems from exacerbation of old or chronic problems -- Inquire about prior evaluations and prior and current treatments -- Provide initial primary care intervention for problems that are not disorders -- Provide extended evaluations and interim check-ins, if needed -- Preparing the practice -- Assessment of disorders, formulation, and feedback -- Overview -- Assessment -- Determine if medication is indicated -- Recognize need for referral -- Formulation -- Feedback -- Before prescribing -- Nonmedication interventions -- Informed consent -- Specific consent issues -- Off-label prescribing -- US Food and Drug Administration boxed warnings -- Important considerations for safe and effective prescribing -- Part III. Group 1 medications for specific diagnoses: attention-deficit/hyperactivity disorder, anxiety, and depression. Group 1 medications for attention deficit/hyperactivity disorder -- General guidance -- Methylphenidate -- Amphetamine -- Guanfacine -- Clonidine -- Atomoxetine -- Summary -- Group 1 medications for anxiety and depression -- General guidance -- Group 1 selective serotonin reuptake inhibitors -- Group 1 serotonin and norepinephrine reuptake inhibitor: duloxetine -- Summary -- Part IV. Group 2 (FDA-Approved antipsychotics and mood stabilizers) and group 3 (all other) medications. Group 2 medications: antipsychotics and mood stabilizers -- Rationale -- Antipsychotics -- The mood stabilizer lithium -- Summary -- Group 3 medications -- Other antidepressants -- Other antipsychotics -- Other mood stabilizers -- Anxiolytics -- Sleep aids -- Future considerations -- Part V. Advanced topics. What to do when treatment is not successful -- Understand the limits of evidence-based treatments and protocols -- Reassess diagnoses -- Reassess psychosocial risks and protective factors -- Reevaluate psychotherapies -- Reconsider medication -- Discontinuing group 1 medications -- Switching group 1 medications -- When to consider group 2 antipsychotics or lithium -- When to consider group 3 medications without FDA approval for use in youth -- When to consider drug levels or genetic testing -- Can genotyping improve medication response? -- When to consider consultation or a second opinion -- When to consider referral for all or part of the patient's ongoing behavioral health care -- Appendixes. Assessment and symptom monitoring tools -- Resources for clinicians -- Training resources for clinicians -- Quality ratings for psychotherapies and efficacy data for medications -- Resources for caregivers -- Diagnostic and statistical manual of mental disorders, fifth edition, complete criteria of select diagnoses
Control code
1059269191
Edition
2nd edition.
Extent
1 online resource (xvi, 248 pages)
Form of item
online
Isbn
9781610022002
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Specific material designation
remote
System control number
(OCoLC)1059269191
Label
Pediatric psychopharmacology for primary care, Mark A. Riddle ; contributing editors, Rebecca A. Baum [and seven others]
Publication
Copyright
Note
Revised edition of: Pediatric psychopharmacology for primary care / Mark A. Riddle ; contributing editors, Jane Meschan Foy [and seven others]. [2016]
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
Introduction -- What is this book? -- Selected updates in second edition -- Target audience -- Why now? -- Basic principles -- What about the future? -- Part I. Conceptual framework. Conceptual framework for prescribing psychotropic medications -- Rationale for the conceptual framework -- Group 1 medications for attention-deficit/hyperactivity disorder, anxiety, and depression -- Group 2 medications -- Group 3 medications -- Part II. Practical guidance. The psychosocial assessment in primary care -- Start with inquiry about normative developmental trajectory -- Triage for psychiatric and social emergencies -- Emphasize function -- Assess sleep pattern -- Identify environmental stressors -- Screen for substance use -- Differentiate new problems from exacerbation of old or chronic problems -- Inquire about prior evaluations and prior and current treatments -- Provide initial primary care intervention for problems that are not disorders -- Provide extended evaluations and interim check-ins, if needed -- Preparing the practice -- Assessment of disorders, formulation, and feedback -- Overview -- Assessment -- Determine if medication is indicated -- Recognize need for referral -- Formulation -- Feedback -- Before prescribing -- Nonmedication interventions -- Informed consent -- Specific consent issues -- Off-label prescribing -- US Food and Drug Administration boxed warnings -- Important considerations for safe and effective prescribing -- Part III. Group 1 medications for specific diagnoses: attention-deficit/hyperactivity disorder, anxiety, and depression. Group 1 medications for attention deficit/hyperactivity disorder -- General guidance -- Methylphenidate -- Amphetamine -- Guanfacine -- Clonidine -- Atomoxetine -- Summary -- Group 1 medications for anxiety and depression -- General guidance -- Group 1 selective serotonin reuptake inhibitors -- Group 1 serotonin and norepinephrine reuptake inhibitor: duloxetine -- Summary -- Part IV. Group 2 (FDA-Approved antipsychotics and mood stabilizers) and group 3 (all other) medications. Group 2 medications: antipsychotics and mood stabilizers -- Rationale -- Antipsychotics -- The mood stabilizer lithium -- Summary -- Group 3 medications -- Other antidepressants -- Other antipsychotics -- Other mood stabilizers -- Anxiolytics -- Sleep aids -- Future considerations -- Part V. Advanced topics. What to do when treatment is not successful -- Understand the limits of evidence-based treatments and protocols -- Reassess diagnoses -- Reassess psychosocial risks and protective factors -- Reevaluate psychotherapies -- Reconsider medication -- Discontinuing group 1 medications -- Switching group 1 medications -- When to consider group 2 antipsychotics or lithium -- When to consider group 3 medications without FDA approval for use in youth -- When to consider drug levels or genetic testing -- Can genotyping improve medication response? -- When to consider consultation or a second opinion -- When to consider referral for all or part of the patient's ongoing behavioral health care -- Appendixes. Assessment and symptom monitoring tools -- Resources for clinicians -- Training resources for clinicians -- Quality ratings for psychotherapies and efficacy data for medications -- Resources for caregivers -- Diagnostic and statistical manual of mental disorders, fifth edition, complete criteria of select diagnoses
Control code
1059269191
Edition
2nd edition.
Extent
1 online resource (xvi, 248 pages)
Form of item
online
Isbn
9781610022002
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Specific material designation
remote
System control number
(OCoLC)1059269191

Library Locations

    • Ellis LibraryBorrow it
      1020 Lowry Street, Columbia, MO, 65201, US
      38.944491 -92.326012
    • J. Otto Lottes Health Sciences LibraryBorrow it
      1 Hospital Dr, Columbia, MO, 65201, US
      38.939544 -92.328377
Processing Feedback ...